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Detection and characterization of proteinase K-sensitive disease-related
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Disease-related PrP
Sc [pathogenic PrP (prion protein)] is classic-
ally distinguished from its normal cellular precursor, PrP
C(cell-
ular PrP) by its detergent insolubility and partial resistance to
proteolysis. Although molecular diagnosis of prion disease has
historically relied upon detection of protease-resistant fragments
of PrP
Sc using PK (proteinase K), it is now apparent that a sub-
stantial fraction of disease-related PrP is destroyed by this
protease. Recently, thermolysin has been identiﬁed as a
complementary tool to PK, permitting isolation of PrP
Sc in its
full-length form. In the present study, we show that thermolysin
can degrade PrP
C while preserving both PK-sensitive and PK-
resistantisoformsofdisease-relatedPrPinbothrodentandhuman
prion strains. For mouse RML (Rocky Mountain Laboratory)
prions, the majority of PK-sensitive disease-related PrP isoforms
do not appear to contribute signiﬁcantly to infectivity. In vCJD
(variant Creutzfeldt–Jakob disease), the human counterpart of
BSE (bovine spongiform encephalopathy), up to 90% of total
PrP present in the brain resists degradation with thermolysin,
whereas only ∼15% of this material resists digestion by PK.
Detection of PK-sensitive isoforms of disease-related PrP using
thermolysin should be useful for improving diagnostic sensitivity
in human prion diseases.
Keywords:prion,prionprotein(PrP),scrapie,thermolysin,trans-
missible spongiform encephalopathy, variant Creutzfeldt–Jakob
disease (vCJD).
INTRODUCTION
Prion diseases are fatal neurodegenerative disorders that include
CJD (Creutzfeldt–Jakob disease), GSS (Gerstmann–Str¨ aussler–
Scheinkerdisease),FFI(fatalfamilialinsomnia),kuruandvariant
CJD (vCJD) in humans [1–3]. Their central feature is the post-
translationalconversionofhost-encodedPrP
C [cellularPrP(prion
protein)], into an abnormal isoform, designated PrP
Sc (pathogenic
PrP) [1,2]. Human prion diseases are biologically unique in
that the disease process can be triggered through inherited
germline mutations in the human PrP gene (PRNP), infection
(by inoculation, or in some cases by dietary exposure) with prion-
infected tissue, or by rare sporadic events that generate PrP
Sc
[1–4]. According to the protein-only hypothesis [5], an abnormal
PrP isoform is the principal, if not the sole, component of the
transmissible prion, with prion propagation occurring through
PrP
Sc acting to replicate itself with high ﬁdelity by recruiting
endogenous PrP
C [1,2,6,7]. Within the framework of the protein-
only hypothesis of prion propagation, the distinct clinical and
neuropathological phenotypes that distinguish prion strains are
thought to be determined by the propagation of PrP
Sc isoforms
with divergent physicochemical properties [1,2,7–12].
PrP
Sc is extracted from affected tissue as highly aggregated
detergent-insoluble material that is not amenable to high-resolu-
tion structural techniques. However, FTIR (Fourier-transform
infrared) spectroscopic methods show that PrP
Sc, in distinction
from PrP
C,h a sah i g hβ-sheet content [13,14]. Biochemically,
PrP
Sc can be distinguished from PrP
C by its partial resistance to
proteolysis and its marked insolubility in detergents (for reviews
see [1,15]). Under conditions in which PrP
C exists as a detergent-
soluble monomer and is completely degraded by the non-speciﬁc
protease PK (proteinase K), PrP
Sc exists in an aggregated form
with the C-terminal two-thirds of the protein showing a marked
resistance to proteolytic degradation, leading to the generation
of N-terminally truncated fragments of di-, mono- and non-
glycosylated PrP [1,15].
Although the molecular diagnosis of prion disease has historic-
ally relied upon the detection of PrP
Sc using PK, it has become
apparent that PK-sensitive pathological isoforms of PrP may
have a signiﬁcant role in prion disease pathogenesis [12,16–
21]. In particular, in inherited prion disease, PrP
Sc isoforms may
be generated with unique physicochemical properties, reﬂected
by sensitivity to PK digestion and PrP
Sc/prion infectivity ratios
that can be very different from the PrP
Sc types propagated in
sporadic and acquired forms of human prion disease (for reviews
see [2,3,22]). Accordingly, the development of new diagnostic
tests that do not rely on PK digestion is required, and, in this
context,aconformation-dependentimmunoassay[12]showshigh
diagnostic sensitivity in human prion disease [18]. More recently,
Gough and colleagues reported thermolysin as a complementary
tool to PK. Thermolysin destroys PrP
C in ovine or bovine brain
whileleavingPrP
Sc initsfull-lengthform,therebyallowingtheN-
terminal domain of PrP
Sc to be exploited for improved methods of
prion-disease diagnosis [23] or prion-strain discrimination [24].
In the present study, we now extend these ﬁndings and show
that thermolysin preserves both PK-sensitive and PK-resistant
disease-related isoforms of PrP while concomitantly destroying
PrP
C in both rodent and human brain. Using mouse RML
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(Rocky Mountain Laboratory) prions, we were able to investigate
prion infectivity associated with PK-sensitive PrP isoforms. It is
anticipated that these methods will facilitate detailed biochemical
characterization of PK-sensitive isoforms of disease-related PrP
associated with multiple prion strain/host combinations.
MATERIALS AND METHODS
Prion-infected tissues
Storage and biochemical analysis of human brain samples
was performed with consent from relatives and with approval
from the Local Research Ethics Committee of the Institute of
Neurology/National Hospital for Neurology and Neurosurgery
(London, U.K.). All procedures were carried out in a micro-
biological containment level III facility with strict adherence
to safety protocols. Brain homogenates [10% (w/v)] from
patients with neuropathologically conﬁrmed vCJD or from con-
trol samples of normal human brain were prepared in DPBS
(Dulbecco’s PBS) lacking Ca
2+ or Mg
2+ ions by serial passage
through needles of decreasing diameter or the use of tissue
grinders (Anachem) [10,25]. Brains from 200 terminal CD-1
mice infected with the RML prion strain [26] were homogenized
in DPBS lacking Ca
2+ or Mg
2+ ions using tissue grinders and
pooled to produce 970 ml of 10% (w/v) RML brain homogenate
(designated I6200). Two batches of 18 brains from uninfected
CD-1 mice were homogenized to produce two pools of ∼90 ml
of 10% (w/v) normal CD-1 brain homogenate (designated I7219
and I8402). Similar procedures were used to generate 10%
(w/v) brain homogenates from hamsters terminally infected with
the Sc237 prion strain or from normal uninfected hamsters.
Pooled homogenates were dispensed as aliquots and maintained
at −70◦C until use.
Titration of RML prions in CD-1 mice
All procedures were carried out in a microbiological containment
level III facility with strict adherence to safety protocols. Care of
micewasperformedaccordingtoinstitutionalandnationalanimal
carecommitteeguidelines.RMLbrainhomogenate(I6200)[10%
(w/v)] was serially diluted (10
−1 to 10
−8)u s i n g1% (w/v) normal
CD-1 brain homogenate as diluent. Aliquots of each dilution
were inoculated either intracerebrally (30 μl) or intraperitoneally
(100 μl) into groups of 6 CD-1 mice as described previously
[27–29]. Mice were examined daily and were killed if exhibiting
signs of distress or once a diagnosis of clinical prion disease was
established[30].Infectiouspriontitre(LD50)wascalculatedusing
the Reed–Muench formula [31].
Enzymatic digestion
Thermolysin (EC 3.4.24.27) from Bacillus thermoproteolyticus
rokko was obtained freeze-dried from Sigma–Aldrich. The
speciﬁc enzymatic activity is 50–100 units/mg of protein (where
1 unit liberates 1 μmol of tyrosine/min at pH 7.5 and 37◦Cu s i n g
casein as a substrate). PK (EC 3.4.21.64) from Tritirachium
albumlimber wasobtainedfreeze-driedfromMerck.Thespeciﬁc
enzymatic activity is approx. 30 Anson units/g (where 1 Anson
unit is the amount of enzyme that liberates 1 mmol of Folin-
positive amino acids/min at pH 7.5 and 35◦C using haemoglobin
as a substrate). Stock solutions of 1 mg/ml thermolysin or PK
were prepared in water and aliquots were stored at −70◦C.
Aliquotsof10%(w/v)brainhomogenatesinDPBSweredigested
for variable time periods with thermolysin at a ﬁnal protease
concentration of 100 μg/ml at 70◦Co r3 7◦C, or with PK at a ﬁnal
concentration of 50 μg/ml (mouse brain) or 100 μg/ml (human
brain) at 37◦C. Aliquots of the digests were snap-frozen for
infectivitystudies,orprocessedimmediatelyforanalysisbyeither
immunoblotting or ELISA. Enzymatic deglycosylation of PrP
prior to immunoblotting was accomplished by incubating 20 μl
aliquots of 2% (w/v) SDS and heat-denatured brain homogenate
with1000 unitsofrecombinantPNGaseF(peptideN-glycosidase
F) (New England Biolabs) in buffer containing 1% Nonidet P40
for 2 h at 37◦C according to the manufacturer’s instructions.
Samples were precipitated with 100% acetone for 1 h at −20◦C
and centrifuged at 16100 g for 30 min in a microfuge. Pellets
were resuspended in 1× SDS sample buffer and analysed by
immunoblotting.
PrP immunoblotting
Aliquots of brain homogenate were mixed with an equal volume
of 2× SDS sample buffer [125 mM Tris/HCl (pH 6.8), 20%
(v/v) glycerol, 4% (w/v) SDS, 4% (v/v) 2-mercaptoethanol and
0.02% Bromophenol Blue containing 8 mM 4-(2-aminoethyl)-
benzenesulphonyl ﬂuoride] and immediately transferred to a
100◦C heating block for 10 min. Samples were analysed by
electrophoresis (16% gels) and immunoblotting as described
previously [22,25]. Blots were blocked in PBST [PBS containing
0.05% Tween 20] and 5% (w/v) non-fat dried skimmed milk
powder and probed with the anti-PrP monoclonal antibodies
ICSM 35 (D-Gen), 3F4 (Signet Laboratories) or SAF32 (Spibio)
at0.2 μg/mlﬁnalantibodyconcentrationinPBST.Blotswerede-
veloped using alkaline-phosphatase-conjugated anti-mouse IgG
secondary antibody and chemiluminescent substrate CDP-Star
(Tropix),andvisualizedonBiomaxMRﬁlm(Kodak)asdescribed
previously [25]. Densitometric analysis of PrP was performed by
using Scion Image analysis software (Scion Corporation).
Detergent-solubility studies
Aliquots of 10% (w/v) brain homogenate (20 μl) were treated
with 0.5 μl of benzonase (Benzon nuclease, purity 1; Merck).
Samples were subsequently adjusted with 80 μlo fP B Sa n d
100 μl of PBS containing 4% (w/v) sodium lauroylsarcosine
(Calbiochem) and incubated for 30 min at 37◦C with constant
agitation.Sampleswerethencentrifugedat16100 gfor30 minin
a microfuge to generate soluble (supernatant) or insoluble (pellet)
fractions. Soluble protein in the supernatant was precipitated with
1 ml of cold methanol (−20◦C) and recovered by centrifugation
at 16100 g for 30 min in a microfuge. The original detergent-
insoluble pellets and methanol-precipitated supernatant protein
pellets were re-suspended to a ﬁnal volume of 40 μl with
PBS containing 0.1% (w/v) sodium lauroylsarcosine, and 10 μl
aliquots were either left untreated or digested with thermolysin
(100 μg/ml ﬁnal protease concentration) at 70◦C for 30 min
or PK (50 μg/ml ﬁnal protease concentration) at 37◦Cf o r1h .
Samples were analysed by electrophoresis and immunoblotting
as described above.
ELISA detection of PrP
ELISA was performed using methods described previously
[32] with adaptations. Brain homogenates were treated with
thermolysin (100 μg/ml ﬁnal protease concentration) at 70◦C
or 37◦C or PK (50 or 100 μg/ml ﬁnal protease concentration) at
37◦C for a range of incubation times. Subsequently, 10 μl
aliquots of these samples or untreated brain homogenate and
temperature controls were adjusted with 10 μlo f4 % (w/v)
SDS and heated at 100◦C for 10 min. Samples were centrifuged
at 100 g for 30 s before adjustment with 600 μlo f5 0 m M
Tris/HCl (pH 8.4) containing 2% (v/v) Triton X-100, 2% (w/v)
sodium lauroylsarcosine and 2% (w/v) bovine serum albumin
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(FractionV,proteasefree,Sigma–Aldrich).Aliquots(50 μl)were
transferred into the wells of microtitre plates (Microlon 96W,
Greiner Bio-One) containing immobilized anti-PrP monoclonal
antibodyICSM18(250 ng/well;D-Gen).Afterincubationat37◦C
for1hwithconstantagitation,wellswerewashedwith3×300 μl
of PBST using an automated microplate washer, followed by the
addition of 100 μl of PBS containing 1% Tween 20 and 1 μg/ml
biotinylated anti-PrP monoclonal antibody ICSM35 (D-Gen).
Followingincubationat37◦Cfor1 hwithconstantagitation,wells
werewashedasdetailedabove,followedbytheadditionof100 μl
of PBS containing 1% Tween 20 and a dilution of streptavidin–
horseradish-peroxidaseconjugate(1:10000dilution,Dako).After
incubation at 37◦C for 30 min with constant agitation, wells were
washed with 4×300 μl of PBST. Wells were developed with
100 μl of QuantaBlu working solution (Pierce) and the reactions
were stopped by the addition of 100 μl of QuantaBlu stop
solution(Pierce).Fluorescence(λex =325 nm,λem =425 nm)was
measured on a Tecan spectra image microplate reader.
NaPTA (sodium phosphotungstic acid) precipitation
The use of NaPTA was performed using a protocol adapted from
Safar et al. [12] essentially as described previously [25]. Brieﬂy,
100 μl aliquots of 10% (w/v) brain homogenate were treated
with1 μlofbenzonaseandweresubsequentlyeitherdigestedwith
thermolysin (100 μg/ml ﬁnal protease concentration) at 37◦C
for 90 min or left untreated. Thermolysin digestion was stopped
by the addition of EDTA (10 mM ﬁnal concentration). Samples
were subsequently adjusted with 100 μl of PBS containing 4%
(w/v)sodiumlauroylsarcosine,incubatedat37◦Cfor30 minwith
constant agitation, and then further adjusted with 16.3 μlo fa
stock solution containing 4% (w/v) NaPTA (lacking magnesium
chloride) (pH 7.4) to give a ﬁnal concentration in the sample of
0.3% (w/v). Samples were incubated at 37◦C for 30 min with
constant agitation before centrifugation at 16100 g for 30 min in
a microfuge. After careful isolation of the supernatant, the pellets
were resuspended to 100 μl with PBS. Aliquots were processed
immediately for analysis by ELISA.
Scrapie cell assay
High-sensitivity cell-culture assays for RML prion infectivity
were performed as described previously by Klohn et al. [33].
Brieﬂy, PK1 cells, a highly scrapie-susceptible N2a subclone,
were exposed for 3 days in 96-well plates to serial dilutions
(10
−3 and 10
−4)o f1 0 % (w/v) RML brain homogenate either
untreated or following digestion with thermolysin (100 μg/ml
ﬁnal protease concentration) at 37◦Co r7 0 ◦Co rP K( 5 0 μg/
ml ﬁnal protease concentration) at 37◦C for a range of incubation
times. A serial dilution of untreated 10% (w/v) RML brain
homogenate (3×10
−4 to 3×10
−6) of known infectivity titre was
performed in parallel. Subsequently cells were split and passaged
appropriately for the scrapie cell assay as described previously
[33] and the infectivity titre of each sample was deduced from the
reference preparation.
Statistical analysis
Allexperimentswereconductedatleastthreetimes.Figuresshow
representative data and show means+ −S.E.M. or S.D.
RESULTS
Characterization of RML prion-infected brain homogenate
In order to standardize a large series of experiments, we gener-
ated a 970 ml stock of 10% (w/v) RML prion-infected brain
Table 1 Titration of RML prions in CD-1 mice
Each dilution of 10% (w/v) RML brain homogenate I6200 was performed in 1% normal CD-1
brain homogenate. Mice were inoculated intracerebrally (I.c.) with 30μl of each dilution or
intraperitoneally (I.p.) with 100μl of each dilution, and the incubation periods are reported for
clinically affected animals in days. Results are means+ −S.D. (n 3). n, number of affected
mice; n0, number of inoculated mice.
I.c. inoculation I.p. inoculation
Dilution n/n0 Mean survival time (days) n/n0 Mean survival time (days)
10−1 6/6 134+ −2 6/6 182+ −12
10−2 5/5 152+ −7 6/6 184+ −13
10−3 6/6 154+ −3 6/6 200+ −5
10−4 6/6 162+ −12 6/6 203+ −8
10−5 6/6 167+ −4 6/6 209+ −7
10−6 4/4 211+ −17 1/4 208
10−7 2/6 208, 222 0/6 –
10−8 1/6 287 0/6 –
homogenate from terminally affected CD-1 mice and titrated
this by intracerebral or intraperitoneal inoculation in CD-1 mice
(Table 1). Using the Reed–Muench formula, 10% (w/v) RML
brain homogenate (I6200) has an infectious prion titre of 10
8.3
intracerebral LD50/ml and 10
6.6 intraperitoneal LD50/ml. Exam-
ination of 10% (w/v) RML brain homogenate by immunoblott-
ing before or after standard PK digestion (50 μg/ml PK for 1 h
at 37◦C) showed the expected pattern of PrP bands (Figure 1a).
In the absence of protease digestion, a mixture of full-length
and truncated PrP species is observed. After PK digestion,
the characteristic pattern of N-terminally truncated fragments
of di-, mono- and non-glycosylated PrP is observed, with a
predominance of mono-glycosylated PrP (Figure 1a).
Thermolysin degrades mouse PrPC while preserving
full-length PrPSc
In initial experiments we adapted the methods of Owen et al. [23]
todeterminetheconditionsinwhichthermolysincouldefﬁciently
degrade mouse PrP
C. We found that digestion of 10% (w/v)
normal CD-1 brain homogenate with 100 μg/ml thermolysin
for 30 min at 70◦C efﬁciently degraded PrP
C (Figure 1b).
In agreement with Owen et al. [23], silver-stain analysis of
thermolysin-digested samples revealed that the majority of pro-
teins in the brain homogenate were destroyed by this treatment
(results not shown). In sharp contrast, application of the same
thermolysin digestion conditions to 10% (w/v) RML prion-
infected brain homogenate produced no apparent change in
the PrP fragment pattern and only a modest reduction in the
overall signal intensity (Figure 1b). These results (which are in
accordance with the ﬁndings of Owen et al. [23] using ovine
or bovine brain homogenates) indicate that thermolysin can
efﬁciently degrade mouse PrP
C while leaving PrP
Sc intact. The
presence of full-length PrP in thermolysin-digested RML brain
homogenate was conﬁrmed through the use of an N-terminal-
speciﬁc anti-PrP monoclonal antibody and by deglycosylation.
The SAF32 monoclonal anti-PrP antibody, with an epitope
spanning residues 79–92 of hamster PrP [34], detected all
three full-length PrP glycoforms in thermolysin-digested samples
(Figure 1d). After deglycosylation, thermolysin-resistant PrP
migrated as two bands (Figure 1b) with apparent molecular
massescorrespondingtoeitherfull-lengthPrPoranendogenously
truncated C2 fragment that has been characterized previously
[24,35,36]. Densitometry showed that ∼25% of the total PrP
remaining after 30 min digestion with thermolysin was in the
full-length form. Importantly, short time periods of digestion
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Figure 1 PK and thermolysin digestion of mouse PrP
Brain homogenate [10% (w/v)] from uninfected CD-1 mice (CD-1) and RML prion-infected CD-1 mice (RML) were analysed by immunoblotting in the absence of protease digestion (−)o ra f t e r
digestion(+)withPK(50μg/mlat37◦Cfor1h)(a)orthermolysin(TL)(100μg/mlat70◦C)for30 min(b,d)or90min(c).Non-glycosylatedfull-lengthandendogenouslytruncatedPrPspecies
were detected after deglycosylation with PNGase F (+PNGase). Immunoblots were probed with anti-PrP monoclonal antibodies ICSM35 (a–c)o rS A F 3 2( d). Molecular masses are stated on the
left-hand side (in kDa).
with 100 μg/ml thermolysin at 70◦C appeared to be required
for isolation of full-length PrP
Sc from RML brain homogenate.
Prolonged digestion (90 min) with thermolysin at 70◦C leads
to the generation of truncated PrP, with a migration pattern
equivalent to that observed after digestion with PK (Figure 1c).
As thermolysin has no preferred cleavage sites in the N-terminal
region of PrP [23], the generation of truncated PrP may be
attributable to thermolysin acting at a non-preferred scissile bond
or to the activity of a minor contaminating protease. Truncation
of disease-related PrP by this activity appears to be prion-strain
speciﬁc [24], and these results indicate that the conditions for di-
gestion with thermolysin should be optimized empirically for
different prion strain/host combinations.
Thermolysin-resistant PrP is mainly insoluble and comprises both
PK-sensitive and PK-resistant PrP
In addition to protease resistance, disease-related isoforms of
PrP are deﬁned by their aggregation state and insolubility in
non-denaturing detergents. Therefore we examined the deter-
gent solubility of thermolysin-resistant PrP. Aliquots of brain
homogenatewereincubatedwith2% (w/v)sodiumlauroylsarco-
sine and then centrifuged to generate detergent-soluble super-
natantsanddetergent-insolublepellets.Aliquotsofthesefractions
were subsequently digested with thermolysin or PK or left
untreated. Immunoblot analysis of PrP present in the supernatant
and pellet fractions showed that the majority of thermolysin-
resistant PrP from RML brain is insoluble (Figure 2a). However,
under the same conditions, PrP
C from normal CD-1 brain was
entirelysolubleandwasrecoveredonlyinthesupernatantfraction
(Figure2b).Theseﬁndingsshowthatthermolysin-resistantPrPin
RML brain homogenate has the properties of disease-related PrP.
Notably, we often observed an apparent increase in PrP signal
strengthonimmunoblotsafterdigestionwithPK(e.g.,Figure1a).
Therefore to assess reliably the proportions of total PrP in RML
brain homogenate that are resistant to digestion with either
thermolysin or PK, we used an ELISA protocol that provides
a sensitive means for the immunodetection of denatured PrP
regardless of whether this is derived from PrP
C or PrP
Sc ([32]
and S. Cronier and M. H. Tattum, unpublished work). After
30 min of digestion of RML brain homogenate with 100 μg/ml
thermolysin at 70◦C (conditions that leave PrP
Sc intact and
efﬁciently degrade PrP
C), ∼55% of total PrP was preserved
(Figure 3). In contrast, after 30 min digestion with 50 μg/ml
Figure 2 Thermolysin-resistant PrP from RML brain is mainly insoluble
Aliquots of 10% (w/v) RML brain homogenate (a) or untreated 10% (w/v) normal CD-1 brain
homogenate (b) were diluted 10-fold in the presence of 2% (w/v) sodium lauroylsarcosine
and incubated for 30 min prior to centrifugation at 16 100g for 30min. PrP recovered in the
detergent-insolublepellets(P)ordetergent-solublesupernatants(SN)wasanalysedbefore(−)
or after digestion with thermolysin (TL) (100μg/ml, 70◦C, 30min) or PK (50μg/ml, 37◦C,
1 h) by immunoblotting with the anti-PrP monoclonal antibody ICSM35. Molecular masses are
stated on the left-hand side (in kDa).
PK at 37◦C, only ∼20% of total PrP remained (Figure 3).
After 5 min digestion with these protease concentrations at these
temperatures, PrP
C was completely degraded in normal CD-
1 brain homogenate (Figure 3). At this time point, in RML
brain homogenate, there was an even higher differential between
the PrP remaining after thermolysin (∼85%)o rP K( ∼20%)
treatment. To investigate the reproducibility of this ﬁnding,
instead of using pooled RML brain homogenate, we examined
10% (w/v) brain homogenates prepared from four individual
terminal RML-infected CD-1 mice. After 5 min digestion, the
mean percentages of thermolysin-resistant PrP and PK-resistant
PrP(+ −S.D.)werehighlyreproducible,givingvaluesof91+ −6%
and23+ −3%respectively.Notably,prolongeddigestion(90 min)
with thermolysin leads to further degradation of disease-related
PrP, reaching levels comparable with those seen after digestion
with PK (Figure 3). These results can be correlated with the
immunoblotanalysisofthermolysindigests,whichshowachange
from a mixture of full-length and truncated PrP species at
30 min to only truncated PrP after 90 min (compare Figures 1b
and 1c). Thus the conditions deﬁned here show that for this
prion strain/host combination, disease-related PrP in RML brain
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Figure 3 Measurement of PK-sensitive PrP in RML brain by ELISA
Normal CD-1 (, )a n dR M L( ,  ) brain homogenates [10% (w/v)] were digested with
thermolysin(100μg/mlat70◦C,,;brokenline)orwithPK(50μg/mlat37◦C,, ;solid
line) for a range of incubation times (t). PrP concentration was measured by ELISA in untreated
normalCD-1andRML brainhomogenatesandfollowing proteasedigestion.PrPconcentration
is expressed as a percentage of total PrP present in untreated RML brain homogenate. Results
are means+ −S.E.M. (n=3).
homogenate is degraded at different rates by thermolysin or
PK, with the majority of disease-related thermolysin-resistant
PrP being rapidly degraded by PK under standard digestion
conditions.
The majority of PK-sensitive disease-related isoforms of PrP do not
contribute to RML prion infectivity
Our results show that digestion of 10% (w/v) RML-infected
brainhomogenatewith100 μg/mlthermolysinfor30 minat70◦C
leads to the efﬁcient degradation of PrP
C while preserving both
PK-resistant and PK-sensitive disease-related isoforms of PrP.
To determine whether the PK-sensitive PrP species contribute to
RML prion infectivity, we measured prion infectivity in PK-
andthermolysin-digested brainhomogenateusingthescrapiecell
assay [33] and compared this with the PrP content determined in
parallel by ELISA and immunoblotting. As control experiments,
we ﬁrst investigated the effects of temperature alone on prion
infectivity in non-digested RML brain homogenate. However,
we found that incubation of brain homogenate at 70◦C rapidly
destroyed up to 90% of RML prion infectivity (Figure 4a).
Clearly, exposure to 70◦C is incompatible with conducting
meaningful RML prion infectivity studies, and this ﬁnding is
in close agreement with the temperatures shown to produce
substantial inactivation of other rodent-adapted prion strains
[37]. Accordingly, we investigated the effect of incubating RML
brain homogenate at 37◦C. At this temperature, a reproducible
ﬂuctuation in prion infectivity was observed over a 90 min time
course (Figure 4b). Overall, however, the loss of infectivity at
37◦C was more modest and acceptable than seen at 70◦C, with
∼65%ofstartinginfectivityremainingafter90 minofincubation
(Figure 4b). Importantly, as shown in Figure 5, the majority
of PrP
C from normal CD-1 brain was destroyed after 5 min
incubation with 100 μg/ml thermolysin at 37◦C, with ∼10%
PrP remaining after digestion for 90 min (also see Figure 6). In
normal CD-1 brain homogenate, PrP
C level is around ∼20% of
total PrP present in untreated RML brain homogenate (Figure 3,
compare PrP content at 0 min). Therefore assuming that the
PrP
C expression level is similar in uninfected and RML-infected
CD-1 brains, PrP
C would correspond to only ∼2% of total PrP
in RML brain homogenate after digestion with thermolysin for
90 min at 37◦C.
Figure 4 RML prion infectivity and PrP content following digestion with
thermolysin or PK
For each sample, PrP () was quantiﬁed by ELISA and expressed as a percentage of total PrP
presentintheuntreatedsample.RMLprioninfectivity()wasmeasuredbythescrapiecellassay
and expressed as a percentage of total infectivity present in the untreated sample. (a, b)R M L
brain homogenate [10% (w/v)] incubated without protease at either 70◦C( a)o r3 7◦C( b)f o r
various incubation times (t). (c) RML brain homogenate [10% (w/v)] incubated at 37◦C with
eitherPK(50μg/ml,, ;solidline)orthermolysin(100μg/ml,,;brokenline)at37◦C
for various incubation times (t). Results are means+ −S.E.M. (n=3).
On the basis of these results, we performed comparative
experiments on RML brain homogenate with thermolysin and PK
at 37◦C. After digestion with thermolysin for 90 min, ∼85% of
totalPrPwaspreserved(Figure4candFigure6).Insharpcontrast,
only∼20%oftotalPrPwaspreservedinRMLbrainhomogenate
after the equivalent digestion with PK at 37◦C (Figure 4c). All
thermolysin-resistant PrP in RML brain homogenate (comprising
both the full-length and truncated PrP isoforms) was precipitated
by NaPTA, whereas no PrP
C from thermolysin-digested normal
CD-1 brain was recovered by this treatment (Figure 6). These
results show that disease-related PrP comprises up to 85% of
total PrP present in RML mouse brain homogenate; however,
the majority (∼75%) of these disease-related PrP isoforms are
readily sensitive to rapid digestion by PK. This ﬁnding agrees
well with previous studies of RML-infected mouse brain, which
also showed that only a minority of total disease-related PrP is
PK-resistant [38,39]. Strikingly, contrary to the marked disparity
in PrP content, infectivity titres in both PK- and thermolysin-
treated samples remained closely similar throughout the time
courseofdigestion(Figure4c).After90 mindigestion,∼20%of
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Figure 5 Immunoblot analysis of mouse PrP following digestion with thermolysin or PK at 37◦C
Normal CD-1 (CD-1) or RML (RML) brain homogenates [10% (w/v)] were digested at 37◦C with thermolysin (TL 37◦C) (100μg/ml) or PK (PK 37◦C) (50μg/ml) for a range of incubation times
(t). Equivalent aliquots were analysed by immunoblotting with the anti-PrP monoclonal antibody ICSM35. Molecular masses are stated on the left-hand side (in kDa).
Figure 6 Thermolysin-resistant PrP from RML brain is precipitated by
NaPTA
HomogenatesfromnormalCD-1brain(CD-1,whitebars)orRMLbrain(RML,blackbars)[10%
(w/v)] were either untreated (−) or treated (+) by digestion with thermolysin (TL) (100μg/ml,
37◦C, 90min), precipitated by NaPTA, or sequentially digested with thermolysin (100μg/
ml, 37◦C, 90min) followed by NaPTA precipitation. NaPTA pellets were resuspended to their
original volume in PBS. The concentration of PrP in all samples was measured by ELISA and is
expressed as a percentage of the total PrP present in the respective untreated samples. Results
are means+ −S.E.M. (n=3).
the starting infectivity was present in both samples. These results
indicate that the majority of PK-sensitive thermolysin-resistant
disease-related PrP isoforms do not contribute signiﬁcantly to
RML prion infectivity in cell culture. Immunoblot analysis
(Figure 5) showed that while thermolysin produced no apparent
change in the PrP fragment pattern over the digestion time
course, PK rapidly produced the characteristic pattern of
N-terminally truncated PrP fragments. The close similarity of
prion infectivity seen in both thermolysin-digested and PK-
digested samples suggests that removal of the N-terminus of PrP
with PK does not adversely affect RML prion infectivity, at least
as determined by the scrapie cell assay.
Thermolysin digestion of PrP associated with human and hamster
prion strains
In a further series of experiments, we investigated the ability
of thermolysin to degrade PrP
C while preserving disease-related
isoforms of PrP associated with other prion strains. Under
conditions that efﬁciently degrade hamster and human PrP
C
(Figures 7a and 7b), preservation of intact PrP
Sc was observed
in brain homogenate from patients with vCJD or terminally
clinically affected hamsters propagating the Sc237 prion strain
(Figures 7a and 7b). The presence of full-length PrP
Sc in these
samples was conﬁrmed by immunoblotting with the monoclonal
antibody SAF32 (Figure 7c) or deglycosylation with PNGase F
(results not shown). These ﬁndings, combined with the results of
Owen et al. [23], establish that thermolysin can be used to isolate
full-length PrP
Sc from multiple prion strain/host combinations.
WhilethepresenceofPK-sensitivedisease-relatedPrPhasbeen
documented previously in many prion strain/host combinations,
including prion-infected hamster brain [12,16,20], prion-infected
mouse brain [38,39], scrapie-infected sheep brain [21] and
patients with sporadic CJD [18], this has not been reported in
vCJD brain. Accordingly, using ELISA, we quantiﬁed disease-
related PrP in 10% (w/v) brain homogenates from four patients
with vCJD (Figure 8). Remarkably, up to 90% of total PrP
was resistant to digestion with thermolysin under conditions that
efﬁciently degrade PrP
C in normal human brain (Figure 8). In
contrast, only ∼10–20% of total PrP in vCJD brain resisted
digestion with PK. This ratio was highly reproducible in all
four patients, with mean percentages of thermolysin-resistant
PrP and PK-resistant PrP (+ −S . D . )o f8 3+ −13% and 19+ −6%
respectively.
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Figure 7 Thermolysin digestion of human and hamster brain homogenate
HomogenatesfromnormalSyrianhamsterbrain(SHa),Sc237-infectedSyrianhamsterbrain(Sc237),normalhumanbrain(NB)orvCJDbrain(vCJD)[10%(w/v)]wereanalysedbyimmunoblotting
before (−)o ra f t e r( +) digestion with thermolysin (TL) (100μg/ml, 70◦C, 1 h). Immunoblots were probed with the anti-PrP monoclonal antibodies 3F4 (a, b) or SAF32 (c) and were developed to
show equivalent levels of PrP immunoreactivity in the TL (−) lanes. Molecular masses are stated on the left-hand side (in kDa).
Figure 8 Predominance of thermolysin-resistant PrP in vCJD brain
PrPin10%(w/v)brainhomogenatesfromfourpatientswithvCJDwasmeasuredbyELISAinthe
absenceofproteasedigestion(70◦C,1h)(Total,whitebars)orafterdigestionwiththermolysin
(100μg/ml,1h,70◦C)(TL-res,blackbars)orPK(100μg/ml,1 h,37◦C)(PK-res,greybars).
PrP concentration is expressed as a percentage of the total PrP and the results are means
(n=4) with S.D. <10%. The proportion of PK-sensitive PrP species present after thermolysin
digestionwasestimatedbytheratio(TL-res−PK-res)/TL-resandwas∼80%insamplesfrom
all four vCJD patients.
DISCUSSION
It is becoming increasingly clear that the pathogenesis of both
human and animal prion diseases involves the propagation of
protease-sensitive disease-related isoforms of PrP [12,16–21].
Indeed, in multiple prion strain/host combinations it now appears
that the majority of disease-related PrP may be destroyed by PK
underconditionsthataretypicallyemployedtodetectprototypical
PrP
Sc [18,21]. PK-sensitive disease-related forms of PrP have
been demonstrated by a conformation-dependent immunoassay
[12,18,21,38,39] and by immunoblotting following biochemical
puriﬁcation [16,20], cold PK digestion [17] or immunological
capture [19].
To date, little is known about the physicochemical properties
of PK-sensitive disease-related PrP, and it remains unclear
whetherPK-sensitiveandPK-resistantdisease-relatedPrPspecies
are conformationally distinct or simply comprise different-sized
aggregates of essentially the same PrP conformers [16,20].
In the present study, we now report a simple method for
detectingPK-sensitivedisease-relatedPrPbyshowingthatlimited
digestion with thermolysin not only preserves disease-related
PrP in the full-length form [23], but also preserves a disease-
related PrP fraction that is readily degraded by PK. In RML
brain homogenate, under optimized conditions of proteolysis
which destroy PrP
C, ∼85% of total PrP resists degradation
with thermolysin and is precipitated by NaPTA, whereas only
∼20% of total PrP resists degradation with PK. Using the
scrapie cell assay, which quantiﬁes RML prion infectivity with
a greater accuracy than a conventional mouse bioassay [33],
we were able to quantify prion infectivity in these protease-
digested samples. We found that the thermolysin-resistant PrP
fraction, which preserves the majority of PK-sensitive disease-
related PrP isoforms, contained the same level of infectivity as
the PK-resistant PrP fraction, equivalent to ∼20% of starting
prion infectivity. Thus while the remaining RML prion infectivity
appears to be roughly proportional to the concentration of PK-
resistant PrP, there is a clear uncoupling of disease-related
PrP concentration and prion infectivity in thermolysin-digested
samples. We conclude from these results that the majority of PK-
sensitive disease-related PrP isoforms are non-infectious, at least
when measured by the scrapie cell assay.
The ﬁnding that both PK- and thermolysin-digested brain
homogenates contain only ∼20% of the starting prion infectivity
despite thermolysin-digested samples containing ∼85% of total
homogenate PrP can be interpreted in several ways. Because the
direct inactivation of thermolysin-resistant PrP by the protease
seems unlikely, given the stability of the observed PrP fragment
size, two other possibilities seem more plausible: (i) that ∼80%
of RML infectivity is associated with a minor population of PrP
conformers that are equally sensitive to degradation by PK and by
thermolysin, or (ii) that a non-PrP component of infectious prions
thatmodiﬁesspeciﬁcprioninfectivityismoreefﬁcientlydegraded
by thermolysin than by PK. Of these two possibilities, the former
is more strongly supported by the ﬁndings of other researchers.
Caughey and colleagues have demonstrated that hamster 263K
prions have different-sized PrP aggregates possessing markedly
different speciﬁc prion infectivities [40]. Small PrP aggregates
comprising 14–28 PrP molecules, which represent only a minor
proportion of total hamster PrP, have speciﬁc infectivities ∼70-
fold higher than large PrP aggregates [40]. A similar physical
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distribution of infectious PrP aggregates associated with the
RML prion strain would provide a reasonable physical basis
for our ﬁndings. Given that small PrP aggregates appear to be
more readily accessible to proteolytic degradation [16,20], both
thermolysin and PK may equivalently destroy a subset of PrP
species corresponding to the most infectious prions that account
f o ru pt o8 0% of total infectivity.
The recent results of Requena and colleagues have established
that the PK-sensitive disease-related hamster PrP isolated from
the upper fractions of sucrose-density gradients has the ability to
convert PrP
C into protease-resistant PrP using the PMCA (protein
misfolding cyclic ampliﬁcation) assay [20]. Importantly, because
PK-sensitivedisease-relatedhamsterPrPwasisolatedonthebasis
of density [20], these preparations are unlikely to contain the full
ensemble of PK-sensitive PrP species. While there are of course
caveats when comparing different prion strains and different
methods, our results suggest that the PK-sensitive PrP species
are heterogeneous and that the majority may be non-infectious.
There is increasing evidence that an abnormal PrP species,
distinct from PrP
Sc, may be responsible for neurotoxicity in
prion disease [7]. Clearly, puriﬁcation of thermolysin-resistant
PK-sensitive disease-related PrP is now required for detailed
evaluation of its speciﬁc infectivity in a mouse bioassay and its
possible contributions to neurotoxicity or other roles in prion
disease pathogenesis.
Safar et al. [18] reported previously that 80–90% of dis-
ease-related PrP in sporadic CJD brain is destroyed by PK
and that detection of this fraction by conformation-dependent
immunoassay enhances diagnostic sensitivity. Our ﬁnding that
up to 90% of total PrP in vCJD brain homogenate resists
digestion with thermolysin under conditions that destroy human
PrP
C veriﬁes the proposal [23] that thermolysin may be useful in
the development of high-sensitivity diagnostic tests. Thermolysin
may also be useful in identifying unusual PrP
Sc isoforms in
isolates where undetectable or barely detectable levels of PK-
resistant PrP are observed; for example, in certain inherited prion
diseases [2,41,42] and in atypical prion disease of ruminants
[43,44].Morerecently,Owenetal.[24]havereportedthepotential
value of thermolysin for prion strain discrimination based upon
the variable generation of truncated PrP fragments. Our results
obtained with two distinct prion strains (mouse RML and human
vCJD prions) suggest that measuring the ratio of PK-resistant
disease-related PrP to thermolysin-resistant disease-related PrP
may also be informative in this regard.
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